Gynecology is the broad medical specialty that handles reproductive health across a woman’s lifetime, from menstrual disorders and contraception to menopause management. Gynecologic oncology is a surgical subspecialty within that field, focused specifically on cancers of the female reproductive system. The distinction matters in concrete ways: a gynecologic oncologist completes years of additional fellowship training in radical pelvic surgery and chemotherapy, and research consistently shows that women with gynecologic cancers fare better when treated by these specialists rather than by general gynecologists or surgeons.
What a General Gynecologist Does
A general gynecologist, often trained alongside obstetrics in what is commonly called an OB/GYN residency, manages a wide range of non-cancerous reproductive health issues. The bread and butter of the practice includes conditions like endometriosis, uterine fibroids, adenomyosis, polycystic ovary syndrome, pelvic pain, abnormal bleeding, and genitourinary symptoms of menopause.1PubMed Central. Management of Common Benign Gynecologic Diseases in Postmenopausal Women These conditions are extremely common and often overlap, meaning a gynecologist may be juggling several of them in a single patient.
Beyond disease management, gynecologists deliver routine preventive care. During a typical preventive visit with an OB/GYN, you are far more likely to receive reproductive health services like a Pap smear than you would at a visit with a generalist physician. One large analysis found Pap tests were provided at roughly 45% of OB/GYN preventive visits compared with about 21% of generalist visits.2PubMed Central. Preventive care visits with OB / GYNs and generalist physicians among reproductive-age women with chronic conditions The trade-off is that non-reproductive health services, such as lipid screening, happen much less often at these visits. General gynecologists also perform surgeries, including hysterectomies, ovarian cyst removals, and procedures for endometriosis, but these operations typically address benign disease rather than cancer.
What a Gynecologic Oncologist Does
A gynecologic oncologist is a physician who has completed an OB/GYN residency and then gone on to fellowship training specifically in performing advanced pelvic surgery and prescribing chemotherapy for women with gynecologic malignancies.3ScienceDirect (Gynecologic Oncology). Delivery of gynecologic oncology care: Optimizing scope of advanced practice providers to enhance patient care The cancers they treat include ovarian, uterine (endometrial), cervical, vulvar, vaginal, and fallopian tube cancers. Some also manage precancerous conditions and complex masses that need to be evaluated for malignancy.
What sets gynecologic oncologists apart from other cancer doctors or surgeons is that they serve as both the surgeon and the medical oncologist for their patients. A woman diagnosed with ovarian cancer, for example, might have the same gynecologic oncologist performing her debulking surgery and then overseeing her chemotherapy regimen. This integrated role is unusual in cancer care, where surgical and medical oncology are typically handled by different specialists.
The Training Gap
Both paths start with medical school and a four-year OB/GYN residency, where trainees learn pelvic anatomy, surgical technique, and general reproductive care.4PubMed Central. Resident perception of Obstetrics and Gynecology(OBGYN) residency pelvic anatomy curriculum: a national study After residency, the paths diverge sharply. A general gynecologist can enter practice immediately. A gynecologic oncologist enters a fellowship lasting three to four additional years.
That fellowship is intensive. According to the American Board of Obstetrics and Gynecology, fellows must spend 12 months of protected time doing research, take dedicated courses in biostatistics and cancer biology, and produce a thesis of publishable quality. The clinical training emphasizes day-to-day surgical and oncologic skills gained during patient care, supported by formal education including lectures and assigned reading.5PubMed. Surgical education and training program development for gynecologic oncology: American perspective Programs must have dedicated faculty, adequate clinical volume, and appropriate facilities. The result is a surgeon comfortable with radical procedures that most general gynecologists would not attempt.
How Surgical Approaches Differ
Both general gynecologists and gynecologic oncologists operate, but the scope and aggressiveness of their surgeries are quite different. In general gynecology, minimally invasive surgery has become the standard of care for many conditions.6PubMed Central. Recent advances in benign gynecological laparoscopic surgery At some centers, well over 90% of hysterectomies for benign disease are now performed laparoscopically.7Journal of Gynecologic Surgery. Increasing the Rate of Laparoscopic Hysterectomy Safely for Benign Gynecologic Disease These are still technically demanding operations, but the surgical goals are usually straightforward: remove the problematic tissue while preserving as much healthy anatomy as possible.
Gynecologic oncology surgery can be a different animal entirely. When treating advanced ovarian cancer, for example, the goal of debulking surgery is to remove as much visible cancer as possible, even if that means performing what are called ultraradical procedures like splenectomy or diaphragm resection. Research shows that survival rates improve when the surgical approach is aggressive enough to achieve optimal debulking.8PubMed Central. Surgical Debulking of Ovarian Cancer: What Difference Does It Make? This willingness to operate in the upper abdomen and beyond the pelvis is something fellowship training specifically prepares gynecologic oncologists for, and it is a skill set most general gynecologists and even many general surgeons do not possess.
Why the Specialist Matters for Cancer Outcomes
The question of which surgeon operates has real consequences. A study published in the Journal of the National Cancer Institute found that survival among ovarian cancer patients operated on by gynecologic oncologists was better than among those operated on by general surgeons.9PubMed. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients Another study looking specifically at ovarian carcinoma found that patients who had surgery by gynecologic oncologists had significantly better five-year survival rates at every stage of disease: 86% vs. 70% for early-stage and 21% vs. 13% for advanced-stage disease.10PubMed. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma
A systematic review pulled the pattern together, finding that surgery by a gynecologic oncologist resulted in a five- to eight-month median survival benefit for patients with advanced-stage disease.11Gynecologic Oncology. The outcomes of ovarian cancer treatment are better when provided by gynecologic oncologists and in specialized hospitals: A systematic review These are not small differences. For endometrial cancer, the picture is similar: adherence to treatment guidelines is associated with better survival, and gynecologic oncologists are more likely to deliver guideline-adherent care. In one analysis, nonadherence to treatment guidelines was associated with a roughly 59% increase in the risk of death compared to guideline-adherent treatment.12PubMed Central. Guideline-adherent treatment, sociodemographic disparities, and cause-specific survival for endometrial carcinomas
Looking at population-level trends, cervical and endometrial cancer death rates in New York State declined over a period that coincided with increases in the number of gynecologic oncology specialists trained and greater emphasis on gynecologic cancer in physician education more broadly.13PubMed Central. Mortality rates due to gynecologic cancers in New York state by demographic factors and proximity to a Gynecologic Oncology Group member treatment center: 1979-2001 While many factors contributed to those declines, the growth of the subspecialty appears to be part of the story.
When You Would Be Referred to a Gynecologic Oncologist
Most women never need to see a gynecologic oncologist, and most gynecologic conditions are managed perfectly well by a general gynecologist. The referral typically happens in one of a few situations: a confirmed or strongly suspected gynecologic cancer, a suspicious pelvic mass, or an abnormal biopsy result that suggests malignancy or a high-risk precancerous condition.
For pelvic masses, professional guidelines from ACOG and the Society of Gynecologic Oncology recommend referral to a gynecologic oncologist when certain red flags are present. These include elevated CA-125 levels (above 200 U/mL in premenopausal women or above 35 U/mL in postmenopausal women), a fixed or nodular pelvic mass, evidence of metastatic disease, ascites, or a strong family history of breast or ovarian cancer.14MDPI. Accuracy in Referrals to Gynecologic Oncologists Based on Clinical Presentation for Ovarian Mass These criteria exist to help general gynecologists triage appropriately, routing women who may have cancer to the subspecialist best equipped to handle it while avoiding unnecessary referrals for clearly benign cysts.
Women with known hereditary cancer syndromes, particularly BRCA1/BRCA2 mutations or Lynch syndrome, may also work with gynecologic oncologists to plan risk-reducing surgeries like preventive removal of the ovaries and fallopian tubes.15PubMed Central. Vaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) in Risk-Reducing Gynecologic Cancer Surgery: A New Frontier in Hereditary Cancer Prevention These are high-stakes decisions that benefit from a specialist’s understanding of cancer risk and surgical technique.
Targeted Therapies and Beyond-Surgery Treatment
Another area where gynecologic oncology diverges from general gynecology is in the use of systemic cancer treatments. General gynecologists do not prescribe chemotherapy or manage targeted therapy regimens. Gynecologic oncologists do, and the field has expanded considerably beyond traditional chemotherapy. Key molecular pathways involved in gynecologic cancers, such as the PI3K/AKT/mTOR pathway, which is overactivated in roughly 70% of ovarian cancers and is also involved in endometrial and cervical cancers, have become targets for newer drugs.16PubMed Central. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence PARP inhibitors, immunotherapy agents, and antiangiogenic drugs have all entered routine gynecologic oncology practice in recent years, and keeping up with this rapidly evolving landscape is a core part of the subspecialty.
This treatment complexity is one reason why the multidisciplinary tumor board has become a fixture of gynecologic oncology care. These weekly conferences bring together gynecologic oncologists, pathologists, radiologists, radiation oncologists, and other specialists to review individual cases. Research shows these boards lead to meaningful changes in patient management: one study found that careful pathology review at a tumor board resulted in altered clinical management for about 20% of patients discussed.17PubMed. Impact of a weekly multidisciplinary tumor board conference on the management of women with gynecologic malignancies They also facilitate clinical trial enrollment, with patients identified by the tumor board being roughly 2.5 times as likely to enroll in a trial.18PubMed Central. Addressing clinical trials: can the multidisciplinary Tumor Board improve participation? A study from an academic women’s cancer program
Genetic Risk and Preventive Surgery
Hereditary cancer syndromes sit at the intersection of gynecology and gynecologic oncology. A general gynecologist might be the first to flag a suspicious family history and order genetic testing, but managing the results often brings a gynecologic oncologist into the picture. BRCA1 and BRCA2 carriers have substantially elevated risks of tubo-ovarian cancer, and the timing and technique of risk-reducing salpingo-oophorectomy depend on which gene is involved, since BRCA1 and BRCA2 carry different age-specific risk profiles.19International Health Sciences Review. Hereditary ovarian cancer: BRCA-Associated risk, screening limitations, and risk-reduction strategies
The decision to remove healthy ovaries and fallopian tubes is not simple. It substantially reduces tubo-ovarian cancer risk and is associated with improved survival, but it also triggers premature menopause, which carries its own quality-of-life and long-term health consequences. Effective prevention requires gene-specific timing, individualized counseling, technically complete surgery, and careful management of the resulting menopause. This kind of nuanced, high-stakes counseling is a core competency of gynecologic oncology that falls outside a general gynecologist’s typical scope.
Survivorship and the Handoff Back
After a woman has been treated for a gynecologic cancer, the relationship between these two specialties can shift. In the early years after treatment, the Society of Gynecologic Oncology recommends that surveillance happen within an oncology practice, where the team is attuned to signs of recurrence and late effects of treatment.20SAGE Publications. Surveillance and Care of the Gynecologic Cancer Survivor Later, once a woman transitions to annual follow-up, her care can return to a primary care provider or general gynecologist. This graduated handoff reflects the reality that intensive cancer surveillance requires oncologic expertise, while long-term survivorship care is often better served in a general practice setting closer to the patient’s home.
Fertility preservation is another area where collaboration matters. Many gynecologic cancers strike women of childbearing age, and treatments like radical hysterectomy or chemotherapy can end fertility. Despite being a frequently reported concern among young cancer survivors, fertility preservation education and procedures remain an unmet need.21PubMed. Fertility Preservation in Gynecologic Cancer Ideally, a gynecologic oncologist raises the topic before treatment begins, and a reproductive endocrinologist handles the actual preservation procedures. But the conversation needs to happen fast, and it often falls through the cracks.
Access Problems and Geographic Disparities
Even when the evidence clearly favors specialist care, getting to a gynecologic oncologist is not always easy. More than a third of U.S. counties are farther than 50 miles from the nearest gynecologic oncologist, affecting roughly 14.8 million women. Each year, an estimated 7,600 women with gynecologic cancers may face geography-related barriers to accessing specialist care.22PubMed. Geographic access to gynecologic cancer care in the United States Women in these low-access counties tend to have lower household incomes, and the counties are disproportionately rural.
The specialists themselves are heavily concentrated in urban areas. A survey of gynecologic oncologists found that 72% practiced in urban settings, with 43% at university hospitals. Only 13% practiced in areas with a population under 50,000.23PubMed Central. Geographic disparities in the distribution of the U.S. gynecologic oncology workforce About half of the surveyed specialists acknowledged that geographic disparities exist in their field’s workforce distribution, but many also supported a “center of excellence” model in which rural patients travel to urban centers for care. That model works in theory, but it imposes financial and logistical burdens that not all patients can manage.
Clinical trial access shows a similar pattern. States with higher disaster-related economic vulnerability had fewer gynecologic oncology trials available per capita.24JAMA Network Open. Geographic Disparities in Gynecologic Oncology Clinical Trial Availability in the US Since clinical trials often represent the best available treatment for aggressive cancers, this geographic mismatch means some patients are excluded not only from standard specialist care but from the cutting edge of it.
How the Subspecialty Developed
Gynecologic oncology as a formal subspecialty is relatively young. Over the past several decades, the field has evolved from scattered surgical efforts into a coordinated discipline that combines refined radical surgical techniques, perioperative intensive care management, radiation therapy, and chemotherapy.25PubMed. History of gynecologic oncology subspecialty Formal fellowship training programs became the backbone of this progress, ensuring that each new generation of specialists trained in all available treatment modalities rather than learning only surgery or only medical oncology.
That integration is what makes the field distinctive. Unlike most cancer types where you see one doctor for surgery and another for chemotherapy, gynecologic oncology consolidated these roles. The result is a specialist who can walk a patient through an entire treatment plan, from the operating room through systemic therapy and into surveillance, with continuity that patients in other oncology subspecialties rarely experience. Whether that model will persist as treatments grow more complex and subspecialized remains an open question, but for now it is one of the defining features that separates gynecologic oncology from both general gynecology and from other branches of cancer medicine.